Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Syndax Pharmaceuticals Inc SNDX

Healthcare Biotechnology
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing pipeline of cancer therapies. Its product candidates include revumenib, and axatilimab. It is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute... see more

Recent & Breaking News (NDAQ:SNDX)

Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias

PR Newswire November 6, 2019

Syndax to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 7, 2019

PR Newswire October 31, 2019

Syndax Announces Participation at Four Upcoming Investor Conferences

PR Newswire August 28, 2019

Syndax Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Clinical and Business Update

PR Newswire August 7, 2019

Syndax to Participate in the BTIG Biotechnology Conference

PR Newswire August 5, 2019

Syndax to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 7, 2019

PR Newswire July 31, 2019

Syndax Pharmaceuticals Announces FDA Clearance of IND Application for Targeted Menin Inhibitor SNDX-5613 for Relapsed/Refractory Acute Leukemias

PR Newswire July 10, 2019

Syndax to Present at the JMP Securities Life Sciences Conference

PR Newswire June 13, 2019

Sirnaomics Appoints Allan L. Shaw as Chief Financial Officer

PR Newswire May 28, 2019

Syndax to Present at the UBS Global Healthcare Conference

PR Newswire May 14, 2019

Syndax Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Clinical and Business Update

PR Newswire May 6, 2019

Syndax to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 6, 2019

PR Newswire April 29, 2019

Syndax Pharmaceuticals Presents Updated Phase 2 Data from ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2019 Annual Meeting

PR Newswire April 1, 2019

Mid-Afternoon Market Update: Shoe Carnival Surges On Upbeat Q4 Results; Inpixon Shares Plunge

Benzinga.com  March 27, 2019

Syndax Announces $26.2 Million Offering of Common Stock and Warrants

PR Newswire March 27, 2019

Syndax Pharmaceuticals Reports Fourth Quarter 2018 Financial Results and Provides Clinical and Business Update

PR Newswire March 7, 2019

Syndax to Present at the Cowen 39th Annual Health Care Conference

PR Newswire March 6, 2019

Syndax to Announce Fourth Quarter and Year-end 2018 Financial Results and Host Conference Call and Webcast on March 7, 2019

PR Newswire February 28, 2019

Syndax Announces Clinical Data from its Entinostat Immuno-oncology Program Selected for Two Oral Presentations at the American Association for Cancer Research Annual Meeting 2019

PR Newswire February 27, 2019

New Research: Key Drivers of Growth for Cronos Group, Spectrum Brands, Black Hills, Entercom Communications, CSS Industries, and Syndax Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production

GlobeNewswire February 12, 2019